Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MIRAMAR, FLA., NOV. 14, 2025 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS) (NASDAQ: HCWB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL IMMUNOTHERAPIES TO LENGTHEN HEALTHSPAN BY DISRUPTING THE LINK BETWEEN INFLAMMATION AND DISEASES, TODAY REPORTED FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS FOR ITS THIRD QUARTER ENDED SEPTEMBER 30, 2025.

HCW BIOLOGICS REPORTS THIRD QUARTER 2025 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS

TETRA-VALENT T-CELL ENGAGER DESIGNED TO ADDRESS SHORTFALLS OF BI-SPECIFIC T-CELL ENGAGERS (BITE) RELATED TO MANUFACTURABILITY, SAFETY PROFILE, AND ABILITY TO TREAT A WIDE SPECTRUM OF SOLID TUMORS TETRA-VALENT T-CELL ENGAGER DESIGNED TO ADDRESS SHORTFALLS OF BI-SPECIFIC T-CELL ENGAGERS (BITE) RELATED TO MANUFACTURABILITY, SAFETY PROFILE, AND ABILITY TO TREAT A WIDE SPECTRUM OF SOLID TUMORS

HCW BIOLOGICS PRESENTS PRECLINICAL DATA FOR TRBC-BASED T-CELL ENGAGER PROGRAM AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING

MIRAMAR, FLA., OCT. 16, 2025 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY) (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING INNOVATIVE IMMUNOTHERAPIES TO EXTEND HEALTHSPAN BY TARGETING THE LINK BETWEEN CHRONIC INFLAMMATION AND DISEASE, IS PLEASED TO ANNOUNCE ITS PARTICIPATION IN THE UPCOMING 2025 MAXIM GROWTH SUMMIT, TAKING PLACE FROM OCTOBER 22ND TO 23RD AT THE HARD ROCK HOTEL NYC. THIS PRESTIGIOUS EVENT BRINGS TOGETHER INDUSTRY LEADERS, INNOVATORS, AND PREMIER INSTITUTIONS TO EXPLORE THE LATEST TRENDS AND ADVANCEMENTS ACROSS SEVERAL INDUSTRIES.

HCW BIOLOGICS TO PARTICIPATE IN THE 2025 MAXIM GROWTH SUMMIT

HCW BIOLOGICS INC. (NASDAQ: HCWB) PARTICIPATES IN VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT ABOUT ITS PROPRIETARY T-CELL ENGAGER PROGRAM

WUGEN CLOSED A $115 MILLION EQUITY FINANCING LED BY FIDELITY MANAGEMENT & RESEARCH COMPANY HCW BIOLOGICS HOLDS A MINORITY EQUITY INTEREST IN WUGEN MIRAMAR, FLA., SEPT. 18, 2025 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS), (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL IMMUNOTHERAPIES TO LENGTHEN HEALTHSPAN BY DISRUPTING THE LINK BETWEEN INFLAMMATION AND AGE-RELATED DISEASES, CONGRATULATES WUGEN, INC. (WUGEN) ON ITS RECENTLY ANNOUNCED $115 MILLION EQUITY FINANCING LED BY FIDELITY MANAGEMENT & RESEARCH COMPANY, WITH PARTICIPATION FROM RIVERVEST VENTURE PARTNERS, LIGHTCHAIN CAPITAL, ABINGWORTH, ICG, LYZZ CAPITAL, TYBOURNE CAPITAL MANAGEMENT, AISLING CAPITAL MANAGEMENT, AND OTHER LEADING LIFE SCIENCES INVESTORS.

HCW BIOLOGICS, A SHAREHOLDER OF WUGEN, CONGRATULATES WUGEN ON ITS RECENT SUCCESSFUL EQUITY FINANCING

LEAD PRODUCT CANDIDATE WILL BE ADVANCED TO LATE IND-ENABLING STUDIES TO PREPARE FOR CLINICAL TRIALS FOR EVALUATION IN THE TREATMENT OF SOLID TUMORS

HCW BIOLOGICS DESIGNATES ONE OF ITS PROPRIETARY TRBC-PEMBROLIZUMAB-BASED IMMUNE CHECKPOINT INHIBITORS AS ITS FRANCHISE IMMUNOTHERAPEUTIC FOR INTERNAL CLINICAL DEVELOPMENT

COMPANY'S PEMBROLIZUMAB-BASED IMMUNE CHECKPOINT INHIBITOR EXHIBITED SUCCESS AGAINST SOLID TUMORS IN IND-ENABLING STUDIES BY SIMULTANEOUSLY ACTIVATING IMMUNE CELLS AND PROMOTING THEIR INFILTRATION INTO SOLID TUMORS PRESENTATION AT NOVA SOUTHEASTERN UNIVERSITY ON SEPTEMBER 12, 2025, IN FORT LAUDERDALE, FLORIDA MIRAMAR, FLA., AUG. 25, 2025 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS), (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL IMMUNOTHERAPIES TO LENGTHEN HEALTHSPAN BY DISRUPTING THE LINK BETWEEN INFLAMMATION AND AGE-RELATED DISEASES, ANNOUNCED TODAY THAT ITS SCIENTISTS HAVE SUCCESSFULLY DEVELOPED SECOND-GENERATION, PEMBROLIZUMAB-BASED IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS, PARTICULARLY FOR PANCREATIC AND OVARIAN CANCER, USING ITS NOVEL PROPRIETARY TRBC PRODUCT DISCOVERY AND DEVELOPMENT PLATFORM TECHNOLOGY.

HCW BIOLOGICS TO SHOWCASE ITS NOVEL SECOND-GENERATION IMMUNE CHECKPOINT INHIBITOR IDENTIFIED AS A POTENTIAL GATEWAY TO A MULTI-BILLION DOLLAR MARKET

MIRAMAR, FLA., AUG. 18, 2025 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (THE COMPANY OR HCW BIOLOGICS) (NASDAQ: HCWB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL IMMUNOTHERAPIES TO LENGTHEN HEALTH SPAN BY DISRUPTING THE LINK BETWEEN INFLAMMATION AND AGE-RELATED DISEASES, TODAY REPORTED FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS FOR ITS SECOND QUARTER ENDED JUNE 30, 2025.

HCW BIOLOGICS REPORTS SECOND QUARTER 2025BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS

TETRA-FUNCTIONAL T-CELL ENGAGERS ACTIVATE T CELLS AND SIMULTANEOUSLY REDUCE IMMUNOSUPPRESSION, WITH POTENT AND ANTIGEN-SPECIFIC ANTI-PANCREATIC CANCER ACTIVITIES AT DOSE LEVELS THAT ARE WELL TOLERATED

HCW BIOLOGICS TO SHOWCASE IMPORTANT UPDATES ON IND-ENABLING STUDIES AND PRECLINICAL SUCCESS OF ITS NOVEL MULTI-SPECIFIC T-CELL ENGAGERS AGAINST SOLID TUMORS

MIRAMAR, FLA., JUNE 26, 2025 (GLOBE NEWSWIRE) -- HCW BIOLOGICS INC. (HCWB OR THE COMPANY) (NASDAQ: HCWB), A U.S.-BASED CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING INNOVATIVE IMMUNOTHERAPIES TO EXTEND HEALTHSPAN BY TARGETING THE LINK BETWEEN CHRONIC INFLAMMATION AND DISEASE, ANNOUNCED TODAY THAT IT HAS RECEIVED NOTICE FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) INFORMING THE COMPANY THAT IT HAS REGAINED COMPLIANCE WITH THE NASDAQ CAPITAL MARKET'S MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT AS REQUIRED BY NASDAQ LISTING RULE 5550(B)(1) (THE EQUITY RULE).

HCW BIOLOGICS REGAINS COMPLIANCE WITH NASDAQ CAPITAL MARKET REQUIREMENTS

HCW BIOLOGICS EARNED UPFRONT PAYMENT AND WILL RECOGNIZE REVENUE OF $7.0 MILLION IN Q2 2025 HCW BIOLOGICS EARNED UPFRONT PAYMENT AND WILL RECOGNIZE REVENUE OF $7.0 MILLION IN Q2 2025

HCW Biologics Inc.

HCWB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HCW Biologics Inc.

HCWB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HCWB